Hussain M, Tombal B, Saad F, Fizazi K, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol 2023 Feb 16:JCO2300041. doi: 10.1200/JCO.23.00041.
PMID: 36795843